21Dec 2024
SGLT2 Inhibitors Benefit Post-MI Outcomes

SGLT2 Inhibitors Benefit Post-MI Outcomes

Sodium-glucose cotransporter-2 (SGLT2) inhibitors significantly reduced hospitalization for heart failure, cardiovascular death, all-cause mortality, recurrent myocardial infarction, arrhythmias, and renal injury in post-MI patients. They also improved left ventricular ejection fraction and end-diastolic volume.

  • #cardiology

Like

Save

Share